Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

A Study to Compare the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly to Those of Sitagliptin and Pioglitazone,in Subjects With Type 2 Diabetes Treated With Metformin (DURATION - 2)

19. marts 2015 opdateret af: AstraZeneca

A Randomized, Double-Blind, Parallel-Group, Multicenter Study to Compare the Glycemic Effects, Safety, and Tolerability of Exenatide Long-Acting Release(Once Weekly) to Those of Sitagliptin and a Thiazolidinedione in Subjects With Type 2 Diabetes Mellitus Treated With Metformin

This study will compare the benefits of exenatide once weekly treatment to those achieved by the approved antidiabetic therapies sitagliptin and pioglitazone in subjects whose type 2 diabetes is managed with metformin therapy alone. The safety and tolerability of the three treatment regimens will also be compared.

Studieoversigt

Status

Afsluttet

Betingelser

Intervention / Behandling

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

514

Fase

  • Fase 3

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

  • Forenede Stater
    • Arizona
      • Peoria, Arizona, Forenede Stater
        • Research Site
    • California
      • Artesia, California, Forenede Stater
        • Research Site
      • Concord, California, Forenede Stater
        • Research Site
      • Encino, California, Forenede Stater
        • Research Site
      • Greenbrae, California, Forenede Stater
        • Research Site
      • La Mesa, California, Forenede Stater
        • Research Site
      • Orange, California, Forenede Stater
        • Research Site
      • Walnut Creek, California, Forenede Stater
        • Research Site
      • Whittier, California, Forenede Stater
        • Research Site
    • Colorado
      • Colorado Springs, Colorado, Forenede Stater
        • Research Site
    • District of Columbia
      • Washington, District of Columbia, Forenede Stater
        • Research Site
    • Florida
      • Coral Gables, Florida, Forenede Stater
        • Research Site
      • Deland, Florida, Forenede Stater
        • Research Site
      • Melbourne, Florida, Forenede Stater
        • Research Site
      • Miami, Florida, Forenede Stater
        • Research Site
      • New Port Richey, Florida, Forenede Stater
        • Research Site
    • Georgia
      • Decatur, Georgia, Forenede Stater
        • Research Site
    • Indiana
      • Avon, Indiana, Forenede Stater
        • Research Site
    • Kansas
      • Wichita, Kansas, Forenede Stater
        • Research Site
    • Kentucky
      • Paducah, Kentucky, Forenede Stater
        • Research Site
    • Louisiana
      • Baton Rouge, Louisiana, Forenede Stater
        • Research Site
      • New Orleans, Louisiana, Forenede Stater
        • Research Site
    • Maryland
      • Oxon Hill, Maryland, Forenede Stater
        • Research Site
    • Massachusetts
      • Boston, Massachusetts, Forenede Stater
        • Research Site
    • Michigan
      • Chelsea, Michigan, Forenede Stater
        • Research Site
      • Ypsilanti, Michigan, Forenede Stater
        • Research Site
    • Minnesota
      • St. Louis Park, Minnesota, Forenede Stater
        • Research Site
    • Missouri
      • St. Louis, Missouri, Forenede Stater
        • Research Site
    • Montana
      • Butte, Montana, Forenede Stater
        • Research Site
    • Nebraska
      • Lincoln, Nebraska, Forenede Stater
        • Research Site
    • Nevada
      • Las Vegas, Nevada, Forenede Stater
        • Research Site
    • New York
      • New Hyde Park, New York, Forenede Stater
        • Research Site
      • New Windsor, New York, Forenede Stater
        • Research Site
      • New York, New York, Forenede Stater
        • Research Site
      • Rochester, New York, Forenede Stater
        • Research Site
    • North Carolina
      • Durham, North Carolina, Forenede Stater
        • Research Site
      • Statesville, North Carolina, Forenede Stater
        • Research Site
      • Winston-Salem, North Carolina, Forenede Stater
        • Research Site
    • Ohio
      • Athens, Ohio, Forenede Stater
        • Research Site
      • Cincinnati, Ohio, Forenede Stater
        • Research Site
      • Dayton, Ohio, Forenede Stater
        • Research Site
    • Pennsylvania
      • Philadelphia, Pennsylvania, Forenede Stater
        • Research Site
    • South Dakota
      • Rapid City, South Dakota, Forenede Stater
        • Research Site
    • Tennessee
      • Memphis, Tennessee, Forenede Stater
        • Research Site
    • Texas
      • Austin, Texas, Forenede Stater
        • Research Site
      • Dallas, Texas, Forenede Stater
        • Research Site
      • San Antonio, Texas, Forenede Stater
        • Research Site
    • Virginia
      • Richmond, Virginia, Forenede Stater
        • Research Site
    • Washington
      • Olympia, Washington, Forenede Stater
        • Research Site
      • Spokane, Washington, Forenede Stater
        • Research Site
      • Tacoma, Washington, Forenede Stater
        • Research Site
  • Indien
      • Bangalore, Indien
        • Research Site
      • Indore, Indien
        • Research Site
      • Karnal, Indien
        • Research Site
      • Mumbai, Indien
        • Research Site
      • Pune, Indien
        • Research Site
  • Mexico
      • Toluca, Mexico
        • Research Site
    • Distrito Federal
      • Mexico City, Distrito Federal, Mexico
        • Research Site
    • Jalisco
      • Guadalajara, Jalisco, Mexico
        • Research Site
      • Zapopan, Jalisco, Mexico
        • Research Site
    • Morelos
      • Cuernavaca, Morelos, Mexico
        • Research Site
    • NuevoLeon
      • Monterrey, NuevoLeon, Mexico
        • Research Site

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • Has been diagnosed with type 2 diabetes mellitus
  • Has a hemoglobin-specific A1c fraction (HbA1c) of 7.1% to 11.0%, inclusive, at study start
  • Has a body mass index (BMI)of 25 kg/m2 to 45 kg/m2, inclusive, at study start
  • Has been on a stable treatment regimen of metformin for a minimum of 2 months prior to study start

  • Either is not treated with or has been on a stable treatment regimen with any of the following medications for a minimum of 2 months prior to study start:

    1. Hormone replacement therapy (female subjects)
    2. Oral contraceptives (female subjects)
    3. Antihypertensive agents
    4. Lipid-lowering agents
    5. Thyroid replacement therapy
    6. Antidepressant agents
    7. Drugs known to affect body weight, including prescription medications (e.g. orlistat [XENICAL®], sibutramine [MERIDIA®], topiramate [TOPAMAX®]) and over-the-counter antiobesity agents

Exclusion Criteria:

  • Has been previously exposed to exenatide once weekly
  • Has donated blood within 60 days of study start or is planning to donate blood during the study

  • Currently being treated, or is expected to require or undergo treatment with any of the following treatment-excluded medications:

    1. Exenatide (BYETTA®) or any Dipeptidyl peptidase-4 DPP-4)inhibitor, sulfonylurea (SU), thiazolidinedione (TZD), or glucagon-like peptide (GLP)-1 analog within 3 months prior to study start
    2. Alpha-glucosidase inhibitor, meglitinide, nateglinide, or pramlintide (SYMLIN®) within 30 days of study start
    3. Insulin within 2 weeks of study start or for more than 1 week within 3 months of study start
    4. Systemic corticosteroids by oral, intravenous, or intramuscular route; or potent, inhaled, or intrapulmonary (including ADVAIR®) steroids known to have a high rate of systemic absorption
    5. Drugs interacting with the CYP2C8 enzyme system, including gemfibrozil (LOPID®) and rifampin
  • Has received any investigational drug within 1 month (or five half-lives of investigational drug, whichever is greater) of study start
  • Has previously experienced a clinically significant adverse event (e.g., significant edema) related to TZD or DPP-4 inhibitor use

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Dobbelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: 1
Medicin: exenatid en gang om ugen
subkutan injektion, 2,0 mg, en gang om ugen
Medicin: placebo tablet
oral tablet, once a day
Aktiv komparator: 2
Medicin: sitagliptin
oral tablet, 100mg, once a day
Andre navne:
  • Januvia
Medicin: placebo once weekly
subcutaneous injection, once a week
Aktiv komparator: 3
Medicin: placebo once weekly
subcutaneous injection, once a week
Medicin: pioglitazone
oral tablet, 45mg, once a day

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Change in HbA1c From Baseline to Week 26
Tidsramme: Day 1, Week 26
Absolute change in HbA1c from baseline (Day 1) to Week 26 [Week 26 - Baseline].
Day 1, Week 26

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Percentage of Subjects Achieving HbA1c Target of <7% at Week 26
Tidsramme: Week 26
Percentages of subjects achieving HbA1c target values of <7% at Week 26.
Week 26
Percentage of Subjects Achieving HbA1c Target of <=6.5% at Week 26
Tidsramme: Week 26
Percentages of subjects achieving HbA1c target values of <=6.5% at Week 26.
Week 26
Percentage of Subjects Achieving HbA1c Target of <=6.0% at Week 26
Tidsramme: Week 26
Percentages of subjects achieving HbA1c target values of <=6.0% at Week 26.
Week 26
Change in Body Weight From Baseline to Week 26
Tidsramme: Day 1, Week 26
Change in body weight from baseline (Day 1) to Week 26.
Day 1, Week 26
Change in Fasting Plasma Glucose From Baseline to Week 26
Tidsramme: Day 1, Week 26
Change in fasting plasma glucose from baseline (Day 1) to Week 26.
Day 1, Week 26
Change in Systolic Blood Pressure From Baseline to Week 26
Tidsramme: Day 1, Week 26
Change in systolic blood pressure from baseline (Day 1) to Week 26.
Day 1, Week 26
Change in Diastolic Blood Pressure From Baseline to Week 26
Tidsramme: Day 1, Week 26
Change in diastolic blood pressure from baseline (Day 1) to Week 26.
Day 1, Week 26
Change in Fasting Total Cholesterol From Baseline to Week 26
Tidsramme: Day 1, Week 26
Change in fasting total cholesterol from baseline (Day 1) to Week 26.
Day 1, Week 26
Change in Fasting High-density Lipoprotein (HDL) From Baseline to Week 26
Tidsramme: Day 1, Week 26
Change in fasting HDL from baseline (Day 1) to Week 26.
Day 1, Week 26
Ratio of Fasting Triglycerides at Week 26 to Baseline
Tidsramme: Day 1, Week 26
Ratio of triglycerides (measured in mg/dL) at Week 26 to baseline (Day 1). Log (Postbaseline Triglycerides) - log (Baseline Triglycerides); change from baseline to endpoint is presented as ratio of endpoint to baseline.
Day 1, Week 26
Assessment on Event Rate of Treatment-emergent Hypoglycemic Events
Tidsramme: Day 1 to Week 26
Major hypoglycemia: events that, in the judgment of the investigator or physician, resulted in loss of consciousness, seizure, coma, or other change in mental status consistent with neuroglycopenia, in which symptoms resolved after administration of intramuscular glucagon or intravenous glucose, required third-party assistance, and was accompanied by a blood glucose concentration < 54 mg/dL prior to treatment. Minor hypoglycemia: symptoms consistent with hypoglycemia and blood glucose concentration < 54 mg/dL prior to treatment and not classified as major hypoglycemia.
Day 1 to Week 26

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

AstraZeneca

Samarbejdspartnere

Eli Lilly and Company

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Generelle publikationer

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart

1. januar 2008

Primær færdiggørelse (Faktiske)

1. februar 2009

Studieafslutning (Faktiske)

1. juli 2009

Datoer for studieregistrering

Først indsendt

6. marts 2008

Først indsendt, der opfyldte QC-kriterier

10. marts 2008

Først opslået (Skøn)

17. marts 2008

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Skøn)

7. april 2015

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

19. marts 2015

Sidst verificeret

1. marts 2015

Mere information

Begreber relateret til denne undersøgelse

Nøgleord

Yderligere relevante MeSH-vilkår

Andre undersøgelses-id-numre

  • BCB106 (DURATION - 2)

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Kliniske forsøg med Type 2 diabetes mellitus

Kliniske forsøg med exenatid en gang om ugen

Søg i lignende forsøg

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

CROs by country

CROs in Ethiopia

Betingelser

Sjældne sygdomme

Narkotikainterventioner

Kosttilskud

Sponsor / samarbejdspartnere

Placeringer

Abonner